Stefano Ratti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5390954/publications.pdf

Version: 2024-02-01

58 papers	1,225 citations	331259 21 h-index	414034 32 g-index
59 all docs	59 docs citations	59 times ranked	1567 citing authors

#	Article	IF	Citations
1	Role of PLCÎ³1 in the modulation of cell migration and cell invasion in glioblastoma. Advances in Biological Regulation, 2022, 83, 100838.	1.4	5
2	AEducaAR, Anatomical Education in Augmented Reality: A Pilot Experience of an Innovative Educational Tool Combining AR Technology and 3D Printing. International Journal of Environmental Research and Public Health, 2022, 19, 1024.	1.2	17
3	APR-246â€"The Mutant TP53 Reactivatorâ€"Increases the Effectiveness of Berberine and Modified Berberines to Inhibit the Proliferation of Pancreatic Cancer Cells. Biomolecules, 2022, 12, 276.	1.8	4
4	The wide and growing range of lamin B-related diseases: from laminopathies to cancer. Cellular and Molecular Life Sciences, 2022, 79, 126.	2.4	29
5	Roles of PI3K/AKT/mTOR Axis in Arteriovenous Fistula. Biomolecules, 2022, 12, 350.	1.8	2
6	Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53. Cells, 2022, 11, 794.	1.8	6
7	Impact of phospholipase C Î²1 in glioblastoma: a study on the main mechanisms of tumor aggressiveness. Cellular and Molecular Life Sciences, 2022, 79, 195.	2.4	12
8	Near-Peer Teaching in Human Anatomy from a Tutorsâ€™ Perspective: An Eighteen-Year-Old Experience at the University of Bologna. International Journal of Environmental Research and Public Health, 2022, 19, 398.	1.2	10
9	Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties. Aging, 2022, 14, 3365-3386.	1.4	5
10	Microbiota-Gut-Brain Axis in Neurological Disorders: From Leaky Barriers Microanatomical Changes to Biochemical Processes. Mini-Reviews in Medicinal Chemistry, 2022, 22, .	1.1	3
11	Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression. Cells, 2022, 11, 2155.	1.8	13
12	Cell signaling pathways in autosomal-dominant leukodystrophyÂ(ADLD): the intriguing role of the astrocytes. Cellular and Molecular Life Sciences, 2021, 78, 2781-2795.	2.4	6
13	Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53. Advances in Biological Regulation, 2021, 79, 100780.	1.4	6
14	Clinical and Molecular Insights in Erythropoiesis Regulation of Signal Transduction Pathways in Myelodysplastic Syndromes and Î²-Thalassemia. International Journal of Molecular Sciences, 2021, 22, 827.	1.8	12
15	The whole body donation program at the university of Bologna: A report based on the experience of one of the oldest university in Western world. Annals of Anatomy, 2021, 234, 151660.	1.0	15
16	GSK-3Î² Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals. Cells, 2021, 10, 816.	1.8	19
17	â€œModulating Phosphoinositide Profiles as a Roadmap for Treatment in Acute Myeloid Leukemiaâ€• Frontiers in Oncology, 2021, 11, 678824.	1.3	5
18	Lamin B1 Accumulationâ€™s Effects on Autosomal Dominant Leukodystrophy (ADLD): Induction of Reactivity in the Astrocytes. Cells, 2021, 10, 2566.	1.8	3

#	Article	IF	Citations
19	Location-dependent role of phospholipase C signaling in the brain: Physiology and pathology. Advances in Biological Regulation, 2021, 79, 100771.	1.4	16
20	Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53. Advances in Biological Regulation, 2021, , 100840.	1.4	4
21	Recent advances in MDS mutation landscape: Splicing and signalling. Advances in Biological Regulation, 2020, 75, 100673.	1.4	7
22	Abilities of Î²-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cells. Advances in Biological Regulation, 2020, 75, 100672.	1.4	9
23	Augmented Reality-Assisted Periosteum Pedicled Flap Harvesting for Head and Neck Reconstruction: An Anatomical and Clinical Viability Study of a Galeo-Pericranial Flap. Journal of Clinical Medicine, 2020, 9, 2211.	1.0	14
24	B-ALL Complexity: Is Targeted Therapy Still A Valuable Approach for Pediatric Patients?. Cancers, 2020, 12, 3498.	1.7	11
25	Subcellular Localization Relevance and Cancer-Associated Mechanisms of Diacylglycerol Kinases. International Journal of Molecular Sciences, 2020, 21, 5297.	1.8	14
26	Cancer therapy and treatments during COVID-19 era. Advances in Biological Regulation, 2020, 77, 100739.	1.4	30
27	Phospholipase C beta1 (PIâ€PLCbeta1)/Cyclin D3/protein kinase C (PKC) alpha signaling modulation during ironâ€induced oxidative stress in myelodysplastic syndromes (MDS). FASEB Journal, 2020, 34, 15400-15416.	0.2	5
28	Targeting GSK3 and Associated Signaling Pathways Involved in Cancer. Cells, 2020, 9, 1110.	1.8	146
29	Nuclear Inositides and Inositide-Dependent Signaling Pathways in Myelodysplastic Syndromes. Cells, 2020, 9, 697.	1.8	11
30	An early scientific report on acromegaly: solving an intriguing endocrinological (c)old case?. Hormones, 2020, 19, 611-618.	0.9	0
31	Glycogen Synthase Kinase-3 and phospholipase C-beta signalling: Roles and possible interactions in myelodysplastic syndromes and acute myeloid leukemia. Biochimica Et Biophysica Acta - Molecular Cell Research, 2020, 1867, 118649.	1.9	8
32	Phosphoinositide-Dependent Signaling in Cancer: A Focus on Phospholipase C Isozymes. International Journal of Molecular Sciences, 2020, 21, 2581.	1.8	47
33	Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines. Aging, 2020, 12, 10194-10210.	1.4	15
34	Phosphoinositide 3 Kinase Signaling in Human Stem
Cells from Reprogramming to Differentiation: A Tale
in Cytoplasmic and Nuclear Compartments. International Journal of Molecular Sciences, 2019, 20, 2026.	1.8	24
35	Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells. Advances in Biological Regulation, 2019, 73, 100633.	1.4	25
36	Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals. Advances in Biological Regulation, 2019, 72, 22-40.	1.4	10

#	Article	IF	Citations
37	Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes. Leukemia, 2019, 33, 2276-2290.	3.3	25
38	Inositide-Dependent Nuclear Signalling in Health and Disease. Handbook of Experimental Pharmacology, 2019, 259, 291-308.	0.9	5
39	Phospholipase C-Î²1 interacts with cyclin E in adipose- derived stem cells osteogenic differentiation. Advances in Biological Regulation, 2019, 71, 1-9.	1.4	17
40	Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells. Advances in Biological Regulation, 2019, 71, 172-182.	1.4	34
41	Nuclear phospholipase C isoenzyme imbalance leads to pathologies in brain, hematologic, neuromuscular, and fertility disorders. Journal of Lipid Research, 2019, 60, 312-317.	2.0	25
42	Metformin influences drug sensitivity in pancreatic cancer cells. Advances in Biological Regulation, 2018, 68, 13-30.	1.4	45
43	Current therapy and new drugs: a road to personalized treatment of myelodysplastic syndromes. Expert Review of Precision Medicine and Drug Development, 2018, 3, 23-31.	0.4	1
44	Nuclear translocation of PKCâ€•Î± is associated with cell cycle arrest and erythroid differentiation in myelodysplastic syndromes (MDSs). FASEB Journal, 2018, 32, 681-692.	0.2	24
45	Effects of berberine, curcumin, resveratrol alone and in combination with chemotherapeutic drugs and signal transduction inhibitors on cancer cellsâ€”Power of nutraceuticals. Advances in Biological Regulation, 2018, 67, 190-211.	1.4	23
46	Nuclear inositide signaling and cell cycle. Advances in Biological Regulation, 2018, 67, 1-6.	1.4	30
47	Endoscopic endonasal approach to primitive Meckelâ€™s cave tumors: a clinical series. Acta Neurochirurgica, 2018, 160, 2349-2361.	0.9	14
48	Along-tract analysis of the arcuate fasciculus using the Laplacian operator to evaluate different tractography methods. Magnetic Resonance Imaging, 2018, 54, 183-193.	1.0	5
49	Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals. Advances in Biological Regulation, 2018, 69, 16-34.	1.4	27
50	Nuclear Inositide Signaling Via Phospholipase C. Journal of Cellular Biochemistry, 2017, 118, 1969-1978.	1.2	28
51	PLC-Î²1 and cell differentiation: An insight into myogenesis and osteogenesis. Advances in Biological Regulation, 2017, 63, 1-5.	1.4	34
52	Regulation of GSK-3 activity by curcumin, berberine and resveratrol: Potential effects on multiple diseases. Advances in Biological Regulation, 2017, 65, 77-88.	1.4	39
53	Nuclear Localization of Diacylglycerol Kinase Alpha in K562 Cells Is Involved in Cell Cycle Progression. Journal of Cellular Physiology, 2017, 232, 2550-2557.	2.0	26
54	Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs. Aging, 2017, 9, 1477-1536.	1.4	168

#	Article	IF	Citations
55	Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells. Oncotarget, 2017, 8, 76525-76557.	0.8	17
56	Nuclear Phosphatidylinositol Signaling: Focus on Phosphatidylinositol Phosphate Kinases and Phospholipases C. Journal of Cellular Physiology, 2016, 231, 1645-1655.	2.0	48
57	Selective Activation of Nuclear PI-PLCbeta1 During Normal and Therapy-Related Differentiation. Current Pharmaceutical Design, 2016, 22, 2345-2348.	0.9	22
58	Role of Nuclear Inositide Signalling and microRNA Signature in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy. Blood, 2016, 128, 5091-5091.	0.6	0